HAE
Haemonetics Corporation
NYSE: HAE · HEALTHCARE · MEDICAL DEVICES
$52.24
+2.05% today
Updated 2026-06-05
Market cap
$3.55B
P/E ratio
38.15
P/S ratio
2.66x
EPS (TTM)
$2.05
Dividend yield
—
52W range
$47 – $87
Volume
0.8M
WallStSmart proprietary scores
56
out of 100
Grade: C+
Hold
Investment rating
5.3
Growth
C+6.0
Quality
B5.5
Profitability
C+6.7
Valuation
B4/9
Piotroski F-Score
Moderate
1.6
Altman Z-Score
Distress
—
Industry rank
—
View all highly rated stocks (75+) →199 stocks currently score above 75
Price targets
Analyst target
$83.10
+59.07%
12-Month target
$56.83
+8.79%
Intrinsic (DCF)
$86.95
Margin of safety
+33.87%
4 Strong Buy4 Buy3 Hold0 Sell0 Strong Sell
Price chart
Stock snapshot
Strengths
+ Free cash flow $53.28M — positive
+ 33.87% below intrinsic value
Risks
- Altman Z 1.63 — distress zone
Key financials
Revenue Net Income Free Cash Flow
| Metric | 2023 | 2024 | 2025 | 2026 | TTM |
|---|---|---|---|---|---|
| Revenue | $1.17B | $1.31B | $1.36B | $1.33B | $1.33B |
| Net income | $115.40M | $117.56M | $167.68M | $97.31M | $-20.15M |
| EPS | — | — | — | — | $2.05 |
| Free cash flow | $162.87M | $115.45M | $142.45M | $260.44M | $53.28M |
| Profit margin | 9.87% | 8.98% | 12.32% | 7.29% | 7.29% |
Peer comparison
Smart narrative
Haemonetics Corporation trades at $52.24. representing a P/E of 38.15x trailing earnings. Our Smart Value Score of 56/100 indicates the stock is fair. The company scores 4/9 on the Piotroski F-Score. With an Altman Z-Score of 1.63, it sits in the distress. TTM revenue stands at $1.33B. with profit margins at 7.29%. Our DCF model estimates intrinsic value at $86.95.
Frequently asked questions
What is Haemonetics Corporation's stock price?
Haemonetics Corporation (HAE) trades at $52.24, on a P/E of 38.2x and a P/S of 2.7x. Those multiples show what the market is paying for each dollar of earnings and sales, which is the real starting point for judging whether the price is reasonable.
Is Haemonetics Corporation overvalued?
Haemonetics Corporation carries a Smart Value Score of 56/100 (Grade C+), which we rate Hold. That score blends growth, quality, and valuation into one read. Our DCF puts intrinsic value at $86.95 versus the $52.24 price, a 33.9% margin of safety on a cash flow basis.
What is the price target of Haemonetics Corporation (HAE)?
The 12-month analyst consensus target is $83.10, about 59.1% above the current $52.24. A consensus target is the average of Wall Street's 12-month forecasts, so it works as a sentiment gauge rather than a guarantee, and it resets with every earnings cycle.
What is the intrinsic value of Haemonetics Corporation (HAE)?
Our DCF model estimates intrinsic value at $86.95, a +33.9% margin of safety versus today's $52.24. Intrinsic value is what the projected cash flows are worth today. A positive reading means the price sits below that estimate, leaving a cushion if growth holds.
What is Haemonetics Corporation's revenue?
Haemonetics Corporation's trailing twelve-month revenue is $1.33B. Revenue scale anchors the valuation multiples and shows whether growth is reaching the top line, so it is best read alongside margin and growth trends to see if that revenue is getting more profitable over time.
Altman Z-Score?
Haemonetics Corporation's Altman Z-Score is 1.63, which places it in the distress. The Altman Z-Score gauges bankruptcy risk from profitability, leverage, and asset efficiency, and a higher reading points to lower financial distress risk.
Company info
SectorHEALTHCARE
IndustryMEDICAL DEVICES
CountryUSA
ExchangeNYSE
CurrencyUSD
Quick metrics
P/S ratio2.66x
ROE12.22%
Beta0.54
50D MA$62.10
200D MA$63.40
Shares out0.05B
Float0.04B
Short ratio—
Avg volume0.8M
Performance
1 week—
1 month—
3 months—
YTD—
1 year—
3 years—
5 years—